1. Introduction {#sec1}
===============

Breast cancer (BC) is a prevalent cancer among women worldwide, and it has been estimated that there are 71 cases of BC per year for every 100 000 women in Brazil. BC shows some distinctive features concerning age-specific incidence rates \[[@B1]\]. It is one of the most common causes of death among women, and epidemiological studies indicate that the age of onset is slowly, but steadily, becoming lower. This suggests that there may be changes in environmental factors that are affecting BC risk \[[@B2]\].

The risk factors for BC include early age of menarche, delayed menopause, contraceptive use, hormonal replacement therapy, above-average body mass index, exposure to environmental pollutants, smoking, and alcohol use \[[@B1]--[@B3]\]. However, it is generally believed that the initiation of BC is a consequence of cumulative genetic damage, which leads to genetic alterations that result in the activation of proto-oncogenes and the inactivation of tumor suppressor genes \[[@B4]\]. A large number of genetic variants that are associated with BC risk have been identified in genes involved in a wide variety of functions, including steroid hormone metabolism, detoxification of environmental carcinogens, DNA damage repair, and tumor suppression \[[@B5]\].

As observed in drug and chemical metabolism, there is considerable interindividual variability (i.e., polymorphisms) in the conjugation pathways of both estrogen and catechol estrogens. These person-to-person differences, which are attributed to polymorphisms in the genes encoding for the respective enzymes, may define subpopulations of women with higher lifetime exposure to hormone-dependent growth promotion or to cellular damage from particular estrogens and/or estrogen metabolites \[[@B4]\].

Current evidence suggests that the metabolic by-products of estrogens in the body may act as initiators of cellular alterations \[[@B6]\]. Estrogen metabolism products such as quinone-catecholestrogen can bind to DNA and form DNA adducts \[[@B7]\]. The generation of free radicals by metabolic redox cycling between quinone and hydroquinone can damage DNA by causing strand breaks, 8-hydroxylation of purines, and lipid hydroperoxide-mediated DNA modifications \[[@B8]\].

Although still controversial, a number of genes involved in biogenesis (*CYP17*), bioavailability (*CYP1B1* and *CYP1A1*), and degradation (*COMT*) of estrogen compounds contain polymorphisms that could affect susceptibility to BC \[[@B9]\]. They are called low penetrance genes (or sometimes modifier genes) and are, in this instance, defined as genes in which subtle sequence variations or polymorphisms may be associated with a slightly to moderately increased relative risk for BC \[[@B4]\].

The hypothesis of the present study is that polymorphic variants of the estrogen metabolizing genes *CYP17*, *CYP1B1*, *CYP1A1,* and *COMT* may affect the spontaneous levels of chromosome damage in lymphocytes of BC patients and subsequently modulate BC risk.

Therefore, the objective of the present work was to correlate the genotypes of polymorphic variants of the above-mentioned genes with the basal levels of chromosome damage in lymphocytes of untreated BC patients and healthy individuals. Micronucleus assay was employed to determine the extent of baseline chromosome damage in BC patients and controls, and PCR-RFLP was used for genotype analysis.

2. Patients and Methods {#sec2}
=======================

2.1. Subjects {#sec2.1}
-------------

The BC patient group consisted of 62 untreated women diagnosed with *in situ* or invasive ductal breast carcinoma, ranging in age from 25 to 60 years old (mean age, 50.5 years old) and free of any pathology associated with the use of medication that is known to cause DNA damage. The control group consisted of 62 women with ages ranging from 25 to 50 years (mean age, 46.7-years old). They were enrolled in the control group after a detailed investigation in order to ensure that they were free from any breast pathology. They came from the same geographical location, their dietary habits were not appreciably different, and they were not occupationally exposed to genotoxic chemicals. None of the subjects reported alcohol consumption, the use of genotoxic medicine, presence of known inherited genetic disorders or chronic diseases or exposure to ionizing or nonionizing radiation, even for diagnostic or therapeutic purposes, for at least one month prior to enrolling in the study. Patients and controls enrolled in the present study did not report family history of breast and/or ovarian cancer. Characteristics of patients and controls are presented in [Table 1](#tab1){ref-type="table"}. This investigation was approved by the National Ethics Committee (CONEP: 1217/2004) and was performed in accordance with ethical standards. Informed consent of patients and controls was obtained before inclusion in the study and sample collection.

2.2. Blood Sampling {#sec2.2}
-------------------

Samples of venous blood (10 mL) were collected in heparinized and EDTA Vacutainer tubes (Becton Dickinson, NJ, USA) by venepuncture under sterile conditions. The samples were coded, immediately protected from direct light, and processed for genotyping and micronucleus assay.

2.3. Genotype Determination {#sec2.3}
---------------------------

Genomic DNA samples were obtained from blood lymphocytes using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI). Isolated DNA was resuspended in Tris-EDTA buffer (pH 8.0) and stored at −20°C until use.

The T1931C polymorphism of the *CYP17* gene was determined by PCR-RFLP with the following primers: sense, 5′-CAAGGTGAAGATCAGGGTAG-3′ and antisense, 5′-GCTAGGGTAAGCAGCAAGAG-3′. The 145 bp product was digested overnight with 8 U of the restriction enzyme *MspA1I*. The T allele remained intact, but the C allele was digested into 75 and 70 bp fragments. The V432L polymorphism of the *CYP1B1* gene was genotyped with the following primers: sense, 5′-TCACTTGCTTTTCTCTCTCC-3′ and antisense, 5′-AATTTCAGCTTGCCTCTTG-3′. The 650 bp product was digested overnight with 8 U of the restriction enzyme *AcuI*. The Leu allele was digested into 350 and 300 bp fragments. The genotypes of the T3205C polymorphism of the *CYP1A1* gene were determined with the following primers: sense, 5′-TAGGAGTCTTGTCTCATGCCT-3′ and antisense, 5′-CAGTGAAGAGGTGTAGCCGCT-3′. The 340 bp PCR product was digested for 3 h with 5 U of the restriction enzyme *MspI*. The C allele was digested into 200 and 140 bp fragments, whereas the T allele remained intact. The genotypes of the V158M polymorphism of the gene *COMT* were determined with the following primers: sense, 5′-TACTGTGGCTACTCAGCTGT-3′ and antisense, 5′-TGAAGCTGGTGTGAACACCT-3′. The 114 bp PCR product was digested with 5 U of the restriction enzyme *NlaIII*. The Met allele was digested into fragments of 96, 54, 39, and 27 bp, whereas the Val allele was digested into fragments of 54 and 39 bp only.

2.4. Cell Culture and Cytokinesis-Block Micronucleus Assay {#sec2.4}
----------------------------------------------------------

Lymphocyte cultures were prepared combining 0.5 mL of isolated lymphocytes in plasma with 5 mL of complete medium containing 78% of RPMI (Sigma-Aldrich Co., USA), 20% inactivated fetal bovine serum (Gibco-Invitrogen, Denmark), the antibiotics penicillin (5 *μ*g/mL, Sigma-Aldrich Co., USA) and streptomycin (10 *μ*g/mL, Sigma-Aldrich Co., USA), and 2% phytohemagglutinin (Life Technologies, Grand Island, NY, USA) to stimulate cell proliferation. Cultures were incubated at 37°C. After 44 hours of incubation, cytochalasin B (Sigma-Aldrich Co., USA) was added to the cultures to a final concentration of 4 *μ*g/mL, according to the method of Fenech and Morley \[[@B10]\]. One thousand binucleated cells were analyzed per individual and the frequency of binucleated cells micronucleated (BCMN) was determined according to the criteria described by Fenech \[[@B11]\].

2.5. Statistical Analysis {#sec2.5}
-------------------------

The Mann-Whitney statistical test was used to compare BCMN between patients and controls. The frequency of BCMN in different genotypes was analyzed with one-way ANOVA and the statistical differences between groups for BC risk was calculated using Fisher\'s exact test (two-tailed). Crude odds ratios (ORs) were calculated and are given with 95% confidence intervals (CIs). Results were considered significant when *P* \< .05.

3. Results and Discussion {#sec3}
=========================

[Table 1](#tab1){ref-type="table"} compares and shows the homogeneity of BC patients and control groups according to their smoking habits, menopause status, hormone replacement therapy, and full-term pregnancy. Basal level of chromosome damage was measured by micronucleus (MN) assay in lymphocytes from 62 BC patients and 62 age-matched controls, as shown in [Figure 1](#fig1){ref-type="fig"}. BC patients exhibited higher levels of chromosome damage than controls according to BCMN (*P* \< .05).

[Table 2](#tab2){ref-type="table"} shows the genotype distributions in patients and controls according to menopause status. The genotype distributions for all cases were in agreement with those predicted by the Hardy-Weinberg equilibrium. An association between BC occurrence and the C allele of the T1931C polymorphism in the *CYP17* gene was observed in the postmenopause group (OR 4.3; 95% CI 1.3--13.7). *CYP1B1*V432L polymorphism had no association with BC occurrence in pre- and postmenopause women, however, in the premenopause women we observed increased risk to BC when the C allele of *CYP1A1* gene (T3205C polymorphism) was present (OR 10.5; 95% CI 2.6--41.7). *COMT* Met allele was also associated with BC occurrence in premenopause women (OR 3.2; 95% CI 1.1--8.6).

The basal levels of chromosome damage in BC patients and controls among the different genotypes are presented in [Table 3](#tab3){ref-type="table"}. BCMN frequencies were higher in BC than in control group in all genotypes except for Val/Val of *COMT* gene where differences between patients and controls were not significant (*P* = .07).

We also evaluated the influence of different genotypes considering the levels of chromosome damage in patient and control groups individually ([Figure 2](#fig2){ref-type="fig"}). *CYP17* T1931C and *CYP1A1* T3205C polymorphisms had no influence in the frequency of BCMN in patients as well as in controls. However, in control group, *CYP1B1*432L allele was related to increased frequencies of BCMN (*P* = .006). Differently, patients with V158M polymorphism of *COMT*gene presented higher frequencies of BCMN when compared to the wild-type counterparts (*P* = .04).

Finally, we tested the risk to BC in the group of patients and controls that presented frequencies of BCMN higher than the mean (higher than 18.5 BCMN for patients and higher than 9.5 BCMN for controls) ([Table 4](#tab4){ref-type="table"}). *CYP17*, *CYP1B1*, and *CYP1A1* polymorphisms did not modify the occurrence of BC, however, *COMT* V158M polymorphism was more frequent in BC than in control group and resulted in significant OR increasing (OR 3.5; 95% CI 1--11.4).

DNA damage can occur spontaneously or as consequence of exposure to chemical or physical genotoxins. There are modulators that can affect the levels of spontaneous DNA damage, including DNA repair genes, antioxidant defense genes, and estrogen-metabolizing gene polymorphisms that can lead to the accumulation of genotoxic estrogen subproducts. High serum estrogen levels are thought to be a major risk factor for BC \[[@B12]\]. *In vitro* and *in vivo* animal and patient-based studies suggest that estrogens, their metabolic compounds, and the entire biochemical metabolic machinery may play a role in BC carcinogenesis \[[@B13]\]. We can look forward into two different processes by which hormones are related to BC: (i) one involves the binding of estradiol to estrogen receptor (ER) alpha with the stimulation of cell proliferation. Errors in DNA occurring during replication result in fixed mutations when not well repaired; (ii) the other process results from the formation of genotoxic metabolites of estradiol, which can bind to DNA, cause depurination, and also result in mutations. Herein, we focused on the second process. Therefore, in the present study, the relationship between the SNPs in four estrogen-metabolizing genes and basal levels of chromosome damage was examined using lymphocytes of untreated BC women and healthy controls once lymphocytes can circulate for years or even decades, accumulating mutations in their DNA \[[@B14]\].

Results presented here show that the basal levels of chromosome damage detected by MN assay and observed in the control group are in accordance with those previously reported in other control populations of similar age \[[@B15], [@B16]\]. It is well known that MN are formed by the condensation of acentric chromosomal fragments or by whole chromosomes lagging behind during cell division and that this is the only biomarker that allows the evaluation of both clastogenic and aneuploidogenic effects in a vast range of cells, as they are detected in interphase \[[@B17]\]. As we did not observe any statistical difference between smoking and nonsmoking patients or controls (data not shown), we grouped these two subsets together for the analysis of the basal levels of chromosome damage in patients and controls.

The investigation of basal levels of chromosome damage in peripheral lymphocytes of untreated cancer subjects has been previously reported. Baseline levels of DNA damage were significantly higher in bladder cancer patients than in controls \[[@B18]\], and the frequency of MN in stimulated peripheral blood cells from an untreated leukemia population was significantly greater than that in the control group \[[@B19]\]. Similar results were found by Lou et al. \[[@B14]\], who simultaneously investigated both baseline and ionizing radiation-induced (IR) genetic damage in peripheral lymphocytes from 36 cancer patients using MN and comet assays. They found that both spontaneous and IR-induced genetic damages were higher in patients than in controls.

In the present study, the primary objective was to investigate the relationship between the genotypes of polymorphisms in estrogen-metabolizing genes and the extent of endogenous chromosome damage. Although this is not an epidemiological study, the odds ratio for the different genotypes was also examined and displayed interesting findings.

The results presented here show that there is a slight significant relationship between the *CYP17* polymorphism, and BC risk is postmenopausal women, however, we found no correlation between spontaneous chromosome damage and the T1931C polymorphism of *CYP17* gene, which encodes for cytochrome p450C17*α*, a 17*α*-hydroxylase that catalyzes the conversion of pregnenolone and progesterone to 17-OH-pregnenolone and 17-OH-progesterone, respectively \[[@B20]\]. Cytochrome p450C17*α* also has a 17,20-lyase activity that converts hydroxylase products to dehydroepiandrosterone (DHEAS) and androstenedione, respectively, which can be further converted to estrogens and testosterone \[[@B20]\]. It has been hypothesized that certain genotype variants in the *CYP17* gene result in higher hormone levels, leading to an increased risk of BC. However, non-Hispanic white women who were heterozygous or homozygous for the variant allele of *CYP17* had lower estrone, total testosterone, free testosterone, and DHEAS concentrations compared to women homozygous for the wild-type allele \[[@B21]\]. Chen and Pei \[[@B22]\] applied both traditional meta-analysis and Bayesian approach to determine the overall effect of *CYP17* T1931C polymorphism on risk of BC and detected that carriers of C allele were positively associated with risk of BC in postmenopausal women and were inversely related to BC in pre-menopausal women.

The V432L polymorphism of the *CYP1B1* gene is located within a catalytic heme-binding domain in exon 3 \[[@B23]\] and has been analyzed in several independent studies that present controversial results. Chinese women with the Leu/Leu genotype at the L432V polymorphism had a higher risk of BC (OR = 2.0, 95%; CI = 1.0--3.7) \[[@B24]\]. A positive association was also seen in Turkish women but was limited to those with a high body mass index (OR = 2.3, 95%; CI = 1.3--4.2) \[[@B25]\]. In contrast, results presented here showed no association between V432L polymorphism and BC occurrence in pre- or postmenopause women (OR 2.5, 95% CI 0.8--7.5 and OR 0.6, 95% CI 0.2--2.1, resp.). A significant inverse association between the Val allele and BC risk was previously observed in studies of African American or mixed populations \[[@B26]\]. It is interesting to note that in the control group, carriers of the Leu allele exhibited higher levels of DNA damage compared to homozygous wild-type individuals while this was not observed in the patients group. We believe that this difference between patients and controls is mostly due to the increased spontaneous levels of chromosome damage in BC which makes it difficult to identify suitable differences in BCMN between polymorphic and wild-type individuals. It has been described that CYP1B1 catalyzes C4 hydroxylation of estradiol (4-hydroxyestradiol (4-OHE~2~)). This metabolite can undergo metabolic redox cycling to generate free radicals such as superoxide and chemically reactive estrogen semiquinone/quinone intermediates, which can form DNA adducts \[[@B27], [@B28]\]. Anyway, these results suggest further investigation of this polymorphism combined with other low-penetrance gene polymorphisms such as DNA repair in the modulation of spontaneous chromosome damage in healthy women.

Cytochrome P450 1A1 (CYP1A1) is one of the most important phase I enzymes expressed in breast tissue. It catalyzes estrogen 2-hydroxylation, generating the 2-OH estrogen metabolite, which can form DNA adducts \[[@B28], [@B29]\]. The 3205T→C polymorphism in *CYP1A1* is located in the 3′ noncoding region and can affect the modulation of enzymatic activity and thereby the susceptibility risk to BC \[[@B30]\]. The results presented here showed that the frequency of this polymorphism was higher in premenopause BC women than in controls and resulted in association to BC risk (OR 10.5, 95% CI 2.6--41.7), however, it had no effect on the frequency of BCMN in patients or in control group. The rare CT and CC genotypes were detected in 14 patients and three controls, and it, therefore, resulted in an extensive confidence interval (CI). Similar results were observed by Taioli et al. \[[@B30]\] that demonstrated an association between this polymorphism and BC cancer risk in African American women (OR = 9.7 95%, CI 2.0--47.9), and Huang et al. \[[@B31]\] demonstrated the same association in Taiwanese women. Nevertheless, the association observed here must be interpreted with caution considering the number of individuals included in the present study and the fact that C allele is rare.

The catechol-O-methyltransferase (COMT) catalyzes the addition of a methyl group to reactive catechol estrogens, converting them into stable methyloxyestrogen conjugates \[[@B32]\]. In patients group, carriers of Met allele of the *COMT* gene exhibited higher levels of chromosome damage relative to those homozygous for the wild-type allele. Besides, when the analysis considered the association of BC occurrence in individuals that exhibited levels of chromosome damage higher than the mean, Met allele was strongly associated with BC occurrence. This was an interesting finding especially if we consider that biomarkers of susceptibility and risk contribute to the identification of high-risk subgroups of the population, independent of whether they are associated with previous exposure or they are involved in a defined pathway or mechanism \[[@B33]\]. It is known that G to A polymorphism at codon 108 in the *COMT* gene leads to a substitution of methionine to valine, resulting in decreased enzymatic activity and increased thermolability \[[@B34], [@B35]\]. As metabolites of catechol estrogens have the potential to induce oxidative DNA damage and form DNA adducts, the conversion of catechol estrogens into stable conjugates may be important in preventing BC \[[@B32]\]. In a previous study of a Taiwanese population, a strong association between the *COMT* polymorphism and BC risk was observed (OR = 3.5 95%, CI 1.15--13.3) \[[@B31]\].

The correlation between genetic polymorphisms and specific phenotypes was evaluated by Synowiec et al. \[[@B36]\]. They correlated a polymorphism in a DNA repair gene with oxidative DNA damage in 41 BC patients and 48 controls. They demonstrated a strong association between BC occurrence and the C/C genotype of the *RAD51*-135G/C polymorphism, the Ser/Ser genotype of the *OGG1*-Ser326Cys polymorphism and the Lys/Gln genotype of the *XPD*-Lys751Gln polymorphism. In contrast, the G/C genotype of the *RAD*-135G/C polymorphism and the Lys/Lys genotype of the *XPD*-Lys751Gln polymorphism exhibited a protective effect against BC. In this study, the risk of BC was calculated in patients and controls that had higher levels of endogenous oxidative DNA damage.

We previously reported that Brazilian untreated BC patients exhibited higher levels of chromosome damage than healthy controls \[[@B37]\] and that *XRCC3* polymorphism was weakly associated with the risk to BC in those individuals that presented higher levels of chromosome damage \[[@B38]\]. It is well known that DNA damage as detected in peripheral blood represents a surrogate for what would be observed in breast tissue. While the polymorphisms are obviously expressed in both breast tissue and lymphocytes, the level of expression of the genes and in particular, the level of substrate that in our present hypothesis is estradiol, may be and is likely very different within breast tissue and the lymphocytes, however, genome damage in lymphocytes may be correlated with cancer-initiating events in target tissues via a common genetic, dietary, or environmental factor \[[@B39]\]. Therefore, the manifestation of effects of the polymorphisms on levels of the reactive quinones may be quite different in breast tissue and lymphocytes, making extrapolation of the findings being reported to implications for BC quite tenuous. As mentioned above, this is not an epidemiological study and although the limited number of participants, we consider that our results point that polymorphisms in the enzymes involved in the metabolism of estradiol/estrone to reactive quinones that cause DNA damage may represent low penetrance risk factors susceptible of further detailed investigations.

4. Conclusions {#sec4}
==============

It is unknown whether the healthy controls and patients with BC had equal levels of DNA damage before the appearance of clinical symptoms in the patients. It is also unclear whether MN enhancement is a consequence or causative agent of the disease process \[[@B19]\]. However, the followup of those controls who are carriers of Met allele of *CYP1B1* gene that exhibited higher frequencies of BNMN than wild-type counterparts could help to further answer this question.

In conclusion, according to the data presented here both the genetic background of genes involved estrogen metabolism and DNA damage in healthy controls and patients can modulate BC risk reflected by higher chromosomal damage in lymphocytes.
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![Frequency of BCMN in untreated BC women and healthy controls. A total of one thousand binucleated cells were analyzed for MN count in each of 62 BC patients and 62 age-matched controls. Bars represent standard error of mean; \**P* \< .001 significantly different from control group.](JBB2011-571784.001){#fig1}

![Frequency of BCMN in untreated BC women and healthy controls considering the presence of estrogen-metabolizing genes polymorphisms (a) *CYP17*, (b) *CYP1B1*, (c) *CYP1A1*, and (d) *COMT*. A total of one thousand binucleated cells were analyzed for MN count in each of 62 BC patients and 62 age-matched controls. Bars represent standard error of mean; \**P* \< .005 significantly different from the wild type in the control group; ^\#^*P* \< .005 significantly different from the wild type in the patients group.](JBB2011-571784.002){#fig2}

###### 

Characteristics of breast cancer patients and controls.

                        Patients *N* (%)   Controls *N* (%)   *P*
  --------------------- ------------------ ------------------ -----
  Smoking                                                     
   Yes                  14 (22.5)          22 (35.4)          .1
   No                   48 (77.5)          40 (64.6)          
  Menopause status                                            
   Post                 32 (51.6)          23 (37)            .1
   Pre                  30 (48.4)          39 (63)            
  HRT                                                         
   Yes                  20 (32.2)          28 (45.1)          .2
   No                   42 (67.8)          34 (54.9)          
  Full-term pregnancy                                         
   Yes                  44 (70.9)          42 (68.4)          .8
   No                   18 (29.1)          20 (32.2)          

HRT: hormone replacement therapy.

###### 

The genotype frequencies of the *CYP17*, *CYP1B1*, *CYP1A1*, and *COMT* gene variants in breast cancer patients and controls, and after menopause.

  Genotype           Breast cancer patients (*n* = 62)   Controls (*n* = 62)   OR (95% CI)   *P* value                      
  ------------------ ----------------------------------- --------------------- ------------- ----------- ------------------ -----------
  *CYP17*                                                                                                                   
  Premenopause                                                                                                              
   TT                16                                  0.25                  22            0.35        1.0 (reference)    .81
   TC+CC             14                                  0.23                  17            0.27        1.1 (0.4-2.9)      
  Postmenopause                                                                                                             
   TT                11                                  0.18                  16            0.26        1.0 (reference)    **.01**
   TC+CC             21                                  0.34                  7             0.12        4.3 (1.3--13.7)    
  *CYP1B1*                                                                                                                  
  Premenopause                                                                                                              
   Val/Val           6                                   0.1                   15            0.24        1.0 (reference)    .11
   Val/Leu+Leu/Leu   24                                  0.39                  24            0.39        2.5 (0.8--7.5)     
  Postmenopause                                                                                                             
   Val/Val           11                                  0.18                  6             0.1         1.0 (reference)    .56
   Val/Leu+Leu/Leu   21                                  0.33                  17            0.27        0.6 (0.2--2.1)     
  *CYP1A1*                                                                                                                  
  Premenopause                                                                                                              
   TT                16                                  0.25                  36            0.58        1.0 (reference)    **.0004**
   TC+CC             14                                  0.23                  3             0.05        10.5 (2.6--41.7)   
  Postmenopause                                                                                                             
   TT                24                                  0.39                  17            0.27        1.0 (reference)    1.0
   TC+CC             8                                   0.13                  6             0.1         0.9 (0.2--3.2)     
  *COMT*                                                                                                                    
  Premenopause                                                                                                              
   Val/Val           10                                  0.16                  24            0.38        1.0 (reference)    **.02**
   Val/Met+Met/Met   20                                  0.32                  15            0.24        3.2 (1.1--8.6)     
  Postmenopause                                                                                                             
   Val/Val           11                                  0.18                  12            0.2         1.0 (reference)    .2
   Val/Met+Met/Met   21                                  0.34                  11            0.18        2.0 (0.6--6.2)     

###### 

Frequency of micronucleated cells in untreated breast cancer women and controls with different genotypes.

  Genotype           Breast cancer patients (*n* = 62)   Controls (*n* = 62)   *P* value                
  ------------------ ----------------------------------- --------------------- ----------- ------------ -------------
  *CYP17*                                                                                               
   TT                27                                  19 ± 8.9              38          9.3 ± 6.3    \<**.0001**
   TC+CC             35                                  18.2 ± 10.5           24          9.6 ± 5.4    **\<.0001**
  *CYP1B1*                                                                                              
   Val/Val           17                                  18.7 ± 10.5           21          6.7 ± 4.1    **\<.0001**
   Val/Leu+Leu/Leu   45                                  18.5 ± 9.6            41          10.3 ± 5.9   **\<.0001**
  *CYP1A1*                                                                                              
   TT                40                                  19.5 ± 10.2           53          9.9 ± 5.5    **\<.0001**
   TC+CC             22                                  16.7 ± 9              9           9.1 ± 5.3    **.001**
  *COMT*                                                                                                
   Val/Val           21                                  15.2 ± 8.7            34          11.3 ± 6.7   .07
   Val/Met+Met/Met   41                                  20.3 ± 10             28          8.5 ± 4.9    **\<.0001**

MNF: micronucleus frequency; M: mean; SE: standard error; patients compared to controls.

###### 

Estrogen-metabolizing gene polymorphisms in breast cancer patients and controls with frequency of micronucleated cells higher than the mean of each group.

  Genotype           Breast cancer patients (*n* = 27)   Controls (*n* = 26)   OR (95% CI)   *P* value                        
  ------------------ ----------------------------------- --------------------- ------------- ----------- -------------------- ---------
  *CYP17*                                                                                                                     
   TT                12                                  0.44                  9             0.35        1.0 (reference)      .57
   TC+CC             15                                  0.56                  17            0.65        0.6 (0.2--2.0)       
  *CYP1B1*                                                                                                                    
   Val/Val           6                                   0.22                  3             0.12        1.0 (reference)      .46
   Val/Leu+Leu/Leu   21                                  0.78                  23            0.88        0.46 (0.1--2.0)      
  *CYP1A1*                                                                                                                    
   TT                21                                  0.78                  16            0.62        1.0 (reference)      .2
   TC+CC             6                                   0.22                  10            0.38        0.4 (0.1--1.5)       
  *COMT*                                                                                                                      
   Val/Val           6                                   0.22                  13            0.5         1.0 (reference)      **.04**
   Val/Met+Met/Met   21                                  0.78                  13            0.5         **3.5 (1--11.4)↑**   
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